BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Arvinas Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Arvinas Inc.'s drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06991556-10762@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT06991556)
DESCRIPTION:Luxdegalutamide\, phase 2.\nStudy: An Open-label Study of JSB46
 2 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients
  With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)\nEstimated prim
 ary completion: 3 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/luxdegalutamide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06991556
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9103@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Veppanu (Vepdegestrant): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letr
 ozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/vepdegestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548127-9103@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Veppanu (Vepdegestrant): Phase 1/2 readout est. (NCT05548127)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: TACTIVE-U: A Study to Learn About the Study Medicine (V
 epdegestrant) When Given With Other Medicines in People With Advanced or M
 etastatic Breast Cancer (Sub-Study A)\nEstimated primary completion: 24 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vepdegestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5548127
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067140-10762@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Luxdegalutamide: Phase 1/2 readout est. (NCT05067140)
DESCRIPTION:Luxdegalutamide\, phase 1/2.\nStudy: A Study of ARV-766 Given b
 y Mouth in Men With Metastatic Prostate Cancer\nEstimated primary completi
 on: 25 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/luxd
 egalutamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05067140
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047118-10762@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT07047118)
DESCRIPTION:Luxdegalutamide\, phase 2\, Metastatic Castration-Resistant Pro
 state Cancer.\nStudy: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (1
 77Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resista
 nt Prostate Cancer (mCRPC)\nEstimated primary completion: 16 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/luxdegalutamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047118
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9103@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Veppanu (Vepdegestrant): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumo
 rs\nEstimated primary completion: 27 August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vepdegestrant#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206056-10762@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20291109
DTEND;VALUE=DATE:20291110
SUMMARY:Luxdegalutamide: Phase 1/2 readout est. (NCT07206056)
DESCRIPTION:Luxdegalutamide\, phase 1/2.\nStudy: An Open-label Dose Escalat
 ion and Expansion\, Followed by a Phase II Study of Tulmimetostat (DZR123)
  and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Cast
 rate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)\nEstimated primary c
 ompletion: 9 November 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/luxdegalutamide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07206056
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
